The non-existence of effective vaccine against HCV leads the healthcare market in United States to be driven by therapeutics. Vertexs Incivek was amongst the first DAA HCV therapies launched in the US and is the current market leader. Inciveks improved efficacy over the previous standard of care in the treatment of the most prevalent HCV genotype in the US, HCV GT1, which enabled the drug to quickly capture the market. Adverse events associated with Incivek therapy, such as life-threatening skin reactions, and the slow-progressing nature of HCV, has resulted in many patients deciding to forego treatment in order to wait for the launch of a more-tolerable HCV regimen.






Find more at : ... Read more »

The main growth driver for personal accident and health insurance during 2008 to 2012 was the launch of HIV or AIDS insurance by both health and life insurers, which was purchased by a large number of the country's formerly uninsured population. The personal accident and health insurance segment grew at a CAGR of 10.7% during 2008 to 2012. This robust growth was supported by the country's increasing per capita income levels, GDP growth, favorable insurance reforms, and financial and healthcare service expansions.







Find more at : Personal Accident and Health Insurance in South Africa